Skip to main content
. 2024 Jun 10;105:105186. doi: 10.1016/j.ebiom.2024.105186

Fig. 1.

Fig. 1

Kaplan–Meier curves for progression-free survival assessed by investigator. Panel a shows progression-free survival assessed by the investigator in HER2-0 or HER2-low-positive population from PALOMA-2 trial, the relative excess risk due to interaction (RERI) = −0.68 (95% CI −1.43 to 0.08, p = 0.078 based on null hypothesis RERI = 0) with HER2-low-positive and Palbociclib + Letrozole as the reference groups. Panel b shows progression-free survival assessed by the investigator in HER2-0 or HER2-low-positive population from PALOMA-3 trial, the RERI = 0.86 (95% CI −0.23 to 1.95, p = 0.12 based on null hypothesis RERI = 0) with HER2-0 and Palbociclib + Fulvestrant as the reference groups.